Ondansetrom Accord (Ondansetron)

Ondansetron, the active ingredient in Ondansetrom Accord, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetrom Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting following surgical procedures.

Side effects reported with ondansetron are generally mild to moderate, but serious reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reactions: including anaphylaxis. - Serotonin syndrome: especially when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzymes.

Before initiating therapy, clinicians should consider several safety aspects. - Cardiac assessment: evaluate baseline QT interval in patients with cardiac risk factors. - Hepatic function: use caution and consider dose adjustment in moderate to severe hepatic impairment. - Renal function: monitor in patients with renal insufficiency, especially if using injectable forms. - Hypersensitivity: avoid in individuals with known allergy to ondansetron or other 5‑HT3 antagonists. - Concomitant QT‑prolonging drugs: assess risk of additive cardiac effects. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Apomorphine: can cause severe hypotension and loss of consciousness. - Certain anti‑arrhythmics (e.g., quinidine, amiodarone): increase risk of QT prolongation. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Aprepitant: can increase ondansetron concentrations. - Anticholinergic drugs: may exacerbate constipation. - Alcohol: may enhance dizziness and sedation.